THERASENSE INC. –

Alameda, Calif.

Went public 10/12/01 at $19 per share

Filing Range: 6.0 million shares at $18 to $20

Offering Size: $114.0 million

Post Offering Valuation: $723.7 million

Shares Outstanding: 38.08 million shares

Underwriters: US Bancorp Piper Jaffray/SG Cowen Securities/ Thomas Weisel Partners LLC

Company Counsel: Wilson Sonsini Goodrich & Rosati

Manager Counsel: Brobeck Phleger & Harrison LLP

Auditor: Pricewaterhouse Coopers LLP

The Company:

Manufactures minimally invasive glucose monitoring equipment for diabetics. The company offers a product made to use only 300 nanoliters of blood compared with 2.5 microliters needed by traditional monitoring products to obtain an accurate reading. The company also manufactures a wireless unit made to continuously monitor glucose by using a miniaturized subcutaneous sensor.

Venture Backers:

InterWest Partners

Brentwood Venture Capital

Sequoia Capital

Delphi Ventures

Crown Advisors International Ltd.

Lehman Brothers

MedVenture Associates

Financing Rounds:

Number of Round Amount

Round # Round Date Stage Investors ($ thousands)

1 04/01/1997 3 Early Stage 5574.9

2 10/22/1998 6 Expansion 11882.0

3 02/02/2000 2 Expansion 42500.0

4 01/23/2001 9 Expansion 55999.7

Financials:

(Data in $ million except EPS)

Y/E

12/31/00

Total Revenues: $5.5

Net Income: (43.6)

EPS: (2.06)